Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. (Q52885084)
Jump to navigation
Jump to search
scientific article published on 28 January 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. |
scientific article published on 28 January 2013 |
Statements
Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. (English)
Arend von Stackelberg
Lorenz Bastian
Jana Hof
Madlen Pfau
Iduna Fichtner
Cornelia Eckert
Günter Henze
Javier Prada
Karl Seeger
Shabnam Shalapour
28 January 2013
19
6
1445-1457